<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136653</url>
  </required_header>
  <id_info>
    <org_study_id>MP0250-CP201</org_study_id>
    <secondary_id>2016-002771-10</secondary_id>
    <nct_id>NCT03136653</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma</brief_title>
  <official_title>A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular Partners AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molecular Partners AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety, tolerability, pharmacokinetics
      (PK), immunogenicity and biological activity of MP0250 in combination with bortezomib +
      dexamethasone in patients with refractory and relapsed multiple myeloma (RRMM).

      MP0250 is a multi-DARPin with three specificities, able to simultaneously neutralize the
      activities of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF)
      and also to bind to human serum albumin (HSA) to give an increased plasma half-life and
      potentially enhanced tumor penetration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the efficacy of MP0250 plus BOR + DEX based on overall response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>proportion of patients achieving CR, VGPR or PR according to the IMWG criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the safety profile of MP0250 plus BOR + DEX</measure>
    <time_frame>24 months</time_frame>
    <description>type, frequency and severity of adverse events based on CTCAE 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the immunogenicity of MP0250 plus BOR + DEX</measure>
    <time_frame>24 months</time_frame>
    <description>assess anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine PFS of MP0250 plus BOR + DEX</measure>
    <time_frame>24 months</time_frame>
    <description>Time (months) to date of tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine DOR of MP0250 plus BOR + DEX</measure>
    <time_frame>24 months</time_frame>
    <description>duration from first observation of PR to the time of disease progression or death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Estimate efficacy in terms of overall survival (OS) of MP0250 plus BOR + DEX</measure>
    <time_frame>24 months</time_frame>
    <description>OS</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterize the PK of MP0250 plus BOR + DEX</measure>
    <time_frame>24 months</time_frame>
    <description>plasma concentrations over time</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterize potential biomarkers of MP0250 plus BOR + DEX</measure>
    <time_frame>24 months</time_frame>
    <description>biomarkers</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <arm_group>
    <arm_group_label>single arm study MP0250 plus BOR + DEX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm study of MP0250 plus bortezomib + dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MP0250 plus BOR+DEX</intervention_name>
    <description>6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>single arm study MP0250 plus BOR + DEX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with MM who have received ≥2 lines of therapy (including bortezomib and an
             IMiD) and have shown no response (i.e. stable disease) to, have progressed on the most
             recent treatment or have progressed within 60 days of the most recent therapy

          2. Presence of a measurable disease

          3. Eastern Cooperative Oncology Group (ECOG) performance status (0 to 1)

          4. Adequate hepatic function

          5. Absolute neutrophil count (ANC) ≥1000/mm3 at Screening

          6. Hemoglobin ≥8.0 g/dL at Screening.

          7. Platelet count ≥50 000/mm3 at Screening.

          8. Calculated or measured creatinine clearance (CrCl) of ≥ 50 mL/min at Screening based
             on the Cockcroft and Gault formula

          9. Serum albumin concentration ≥ 30 g/L

         10. Males and females ≥18 years of age

         11. Capable of giving signed informed consent

        Exclusion Criteria:

          1. Patients with the following diseases:

             Monoclonal gammopathy of undetermined significance (MGUS) of non- immunoglobulin (Ig)M
             and IgM subtypes, Light chain MGUS, Solitary plasmacytoma (alone or with minimal
             marrow involvement), Systemic Ig light chain amyloidosis, Waldenstrom's
             Macroglobulinemia

          2. Peripheral neuropathy Grade 2 or higher at Screening

          3. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV),
             symptomatic cardiac ischemia, or conduction abnormalities uncontrolled by conventional
             intervention.

          4. Uncontrolled hypertension

          5. Stroke, or transient ischemic attack within 6 months of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director, MPAG</last_name>
    <phone>+41 44 755 7700</phone>
    <email>info@molecularpartners.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Essen, Haematology</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg, Haematology, Oncology</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Würzburg, Haematology, Oncology</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Bari Medical School, Oncology</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Healthcare Institution Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Turin, Oncology</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdańsk, Haematology</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Krakow, Haematology</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Lublin, Haematology</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DARPin</keyword>
  <keyword>MP0250</keyword>
  <keyword>VEGF</keyword>
  <keyword>HGF</keyword>
  <keyword>RRMM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

